Exelixis Inkomsten in het verleden

Verleden criteriumcontroles 5/6

De winst van Exelixis is gedaald met een gemiddeld jaarlijks percentage van -3.4%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19%. De inkomsten zijn groeide met een gemiddeld percentage van 17% per jaar. Het rendement op het eigen vermogen Exelixis bedraagt 20.5% en de nettomarge bedraagt 22.4%.

Belangrijke informatie

-3.4%

Groei van de winst

-3.9%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	17.0%
Rendement op eigen vermogen	20.5%
Nettomarge	22.4%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

May 07

Recent updates

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Oct 31

Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Oct 31

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Jun 14

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

May 24

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

May 07

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

May 02

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Apr 22

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Mar 28

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Feb 26

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Jan 17

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Dec 27

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

May 30

Opbrengsten en kosten

Hoe Exelixis geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:EXEL Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	2,082	467	489	906
30 Jun 24	2,014	350	516	1,016
31 Mar 24	1,847	205	525	1,038
31 Dec 23	1,830	208	543	1,044
30 Sep 23	1,774	92	531	1,136
30 Jun 23	1,714	164	507	1,002
31 Mar 23	1,664	154	488	969
31 Dec 22	1,611	182	460	892
30 Sep 22	1,638	308	440	777
30 Jun 22	1,555	273	426	742
31 Mar 22	1,521	298	402	691
31 Dec 21	1,435	231	402	694
30 Sep 21	1,254	164	385	626
30 Jun 21	1,157	94	371	639
31 Mar 21	1,031	65	333	605
31 Dec 20	988	112	293	548
30 Sep 20	958	152	269	488
30 Jun 20	998	282	232	409
31 Mar 20	979	294	231	376
31 Dec 19	968	321	228	337
30 Sep 19	956	612	223	300
30 Jun 19	910	642	219	247
31 Mar 19	856	650	212	208
31 Dec 18	854	690	206	182
30 Sep 18	745	368	200	157
30 Jun 18	672	323	190	141
31 Mar 18	585	253	179	127
31 Dec 17	452	154	159	112
30 Sep 17	410	150	126	104
30 Jun 17	320	58	120	95
31 Mar 17	257	6	116	90
31 Dec 16	191	-70	116	96
30 Sep 16	124	-147	120	96
30 Jun 16	71	-181	106	101
31 Mar 16	43	-186	83	103
31 Dec 15	37	-162	57	96
30 Sep 15	35	-178	50	113
30 Jun 15	31	-195	42	130
31 Mar 15	30	-229	46	157
31 Dec 14	25	-261	51	189
30 Sep 14	22	-281	55	199
30 Jun 14	21	-286	58	203
31 Mar 14	27	-275	55	201
31 Dec 13	31	-245	51	179

Kwaliteitswinsten: EXEL heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (22.4%) EXEL } zijn hoger dan vorig jaar (5.2%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van EXEL is de afgelopen 5 jaar met 3.4% per jaar gedaald.

Versnelling van de groei: De winstgroei van EXEL over het afgelopen jaar ( 407.1% ) overtreft het 5-jarig gemiddelde ( -3.4% per jaar).

Winst versus industrie: De winstgroei EXEL over het afgelopen jaar ( 407.1% ) overtrof de Biotechs -sector -2.3%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 20.5% ) van EXEL wordt als hoog beschouwd.

Exelixis Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2024

Exelixis, Inc. to Report Q3, 2024 Results on Oct 29, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

Recent updates

Investor sentiment improves as stock rises 20%

Independent Director notifies of intention to sell stock

Price target increased by 7.1% to US$31.60

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2024

Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching

Exelixis, Inc. to Report Q3, 2024 Results on Oct 29, 2024

CEO, President & Director exercised options and sold US$479k worth of stock

Executive VP notifies of intention to sell stock

Exelixis, Inc Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult

Independent Director recently sold US$907k worth of stock

Consensus EPS estimates increase by 37%

Insider notifies of intention to sell stock

Exelixis Comes Up Aces

Exelixis, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $500 million worth of its shares.

Exelixis, Inc. Announces U.S. Food and Drug Administration Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors

Exelixis, Inc. to Report Q2, 2024 Results on Aug 06, 2024

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Independent Director recently sold US$576k worth of stock

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

Independent Director notifies of intention to sell stock

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Exelixis, Inc., Annual General Meeting, May 30, 2024

Exelixis, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Independent Director notifies of intention to sell stock

Executive Vice President of Commercial recently sold US$1.0m worth of stock

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Executive Vice President of Commercial notifies of intention to sell stock

Full year 2023 earnings: EPS exceeds analyst expectations

Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024

Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Executive VP notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Exelixis Announces Initiation of the Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

Exelixis, Inc. Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.23 in 3Q 2022)

Consensus EPS estimates fall by 10%

Exelixis, Inc. Announces Detailed Results from Phase 3 Cabinet Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

Exelixis, Inc. to Report Q3, 2023 Results on Nov 01, 2023

CEO, President & Director exercised options and sold US$2.1m worth of stock

Exelixis, Inc. Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

New major risk - Revenue and earnings growth

Executive Vice President of Commercial recently sold US$632k worth of stock

Consensus EPS estimates increase by 11%

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Executive VP notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Exelixis, Inc. Elects Dave Johnson to its Board of Directors

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023